Affiliation:
1. Department of Cardiology, School of Medicine, Trakya University, Edirne 22030, Turkey
2. Department of Physical Medicine and Rehabilitation, School of Medicine, Trakya University, Edirne 22030, Turkey
Abstract
Rheumatoid arthritis (RA) is the most common rheumatologic disease characterized by inflammation with a definite relationship with heart disease. Impaired immunity, chronic inflammation, genetic susceptibility, autonomic nervous system (ANS) dysfunction, altered metabolic profile have been blamed for ischemic and non-ischemic heart diseases in RA patients. Medications used in RA treatment can also modify the risk of heart diseases by different mechanisms. Understanding the pathogenesis is essential to prevent early cardiac dysfunction in RA patients. Fundamental cellular and molecular mechanisms of pathogenesis await further elucidation. Disease management is of great importance since the cardiovascular (CV) events are known to be reduced with low disease activity. Discovery of new mechanisms will pave the way for the development of novel treatment modalities. This review highlights the epidemiology, pathogenesis, risk factors, diagnosis and screening methods and management of CV comorbidities in RA patients. Besides impact of RA medications and exercise on CV risk are summarized.
Publisher
Open Exploration Publishing
Subject
General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Medicine,Ocean Engineering,General Medicine,General Medicine,General Medicine,General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Medicine
Reference194 articles.
1. Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res. 2013;56:267–86.
2. Kumar N, Marshall NJ, Hammal DM, Pearce MS, Parker L, Furniss SS, et al. Causes of death in patients with rheumatoid arthritis: comparison with siblings and matched osteoarthritis controls. J Rheumatol. 2007;34:1695–8.
3. Dijkshoorn B, Raadsen R, Nurmohamed MT. Cardiovascular disease risk in rheumatoid arthritis anno 2022. J Clin Med. 2022;11:2704.
4. Kaplan MJ. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am. 2010;36:405–26.
5. Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol. 2017;8:131.